- Home
- SCNX vs GTBP Comparison
SCNX vs GTBP Comparison
Compare SCNX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | GTBP |
|---|---|---|
| Founded | 2010 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 13.0M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SCNX | GTBP |
|---|---|---|
| Price | $0.36 | $6.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 771.9K | 410.6K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,831,778.00 | N/A |
| Revenue This Year | $1,097.38 | N/A |
| Revenue Next Year | $239.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.72 | N/A |
| 52 Week Low | $0.24 | $0.22 |
| 52 Week High | $2.60 | $6.24 |
Technical Indicators
Market Signals| Indicator | SCNX | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 95.15 |
| Support Level | $0.30 | $0.39 |
| Resistance Level | $0.43 | N/A |
| Average True Range (ATR) | 0.03 | 0.26 |
| MACD | -0.01 | 0.65 |
| Stochastic Oscillator | 17.56 | 85.83 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.